Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

VIR

Vir Biotechnology (VIR)

Vir Biotechnology Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VIR
FechaHoraFuenteTítuloSímboloCompañía
31/05/202413:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
31/05/202413:42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
29/05/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
29/05/202415:05Business WireVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
29/05/202407:05Business WireVir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical OfficerNASDAQ:VIRVir Biotechnology Inc
23/05/202415:05Business WireVir Biotechnology to Host 2024 Annual Meeting of StockholdersNASDAQ:VIRVir Biotechnology Inc
22/05/202407:05Business WireMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024NASDAQ:VIRVir Biotechnology Inc
21/05/202407:17Business WireVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024NASDAQ:VIRVir Biotechnology Inc
14/05/202415:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRVir Biotechnology Inc
02/05/202415:05Business WireVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
30/04/202415:05Business WireVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024NASDAQ:VIRVir Biotechnology Inc
18/04/202407:00Business WireVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsNASDAQ:VIRVir Biotechnology Inc
11/04/202415:30Business WireVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024NASDAQ:VIRVir Biotechnology Inc
05/03/202407:05Business WireVir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of ScheduleNASDAQ:VIRVir Biotechnology Inc
26/02/202415:27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRVir Biotechnology Inc
26/02/202415:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRVir Biotechnology Inc
23/02/202407:05Business WireVir Biotechnology to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:VIRVir Biotechnology Inc
22/02/202415:05Business WireVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
20/02/202415:30Business WireVir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical OfficerNASDAQ:VIRVir Biotechnology Inc
13/02/202416:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VIRVir Biotechnology Inc
01/02/202415:05Business WireVir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024NASDAQ:VIRVir Biotechnology Inc
14/12/202304:59IH Market NewsApple Stocks Reach Record, Adobe Faces Stock Drops, Berkshire Hathaway Increases Stake in OXY, and MoreNASDAQ:VIRVir Biotechnology Inc
13/12/202315:05Business WireVir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value CreationNASDAQ:VIRVir Biotechnology Inc
06/12/202315:05Business WireVir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
13/11/202307:00Business WireVir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023NASDAQ:VIRVir Biotechnology Inc
10/11/202307:00Business WireVir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023NASDAQ:VIRVir Biotechnology Inc
08/11/202307:05Business WireVir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™NASDAQ:VIRVir Biotechnology Inc
03/11/202315:33Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VIRVir Biotechnology Inc
03/11/202315:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRVir Biotechnology Inc
02/11/202315:05Business WireVir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:VIR